As the KRAS mutant CRC CTOS lines in the partially responsive group exhibited a partial response while those in the resistant group exhibited no response, we expected that combination therapy may improve the effect of cetuximab in the partially responsive group. This evidence concerns the gene KRAS and colorectal carcinoma.